Eli Lilly has officially introduced its highly sought-after diabetes and weight-loss drug, Mounjaro, in India following approval from the Central Drugs Standard Control Organisation (CDSCO). The launch marks a significant milestone in the country’s battle against rising obesity and diabetes cases, offering a new, first-of-its-kind treatment option for millions of affected individuals.
Mounjaro, chemically known as tirzepatide, is now available in India in a single-dose vial presentation. The pricing for the drug is as follows:
This launch comes at a crucial time, as India is witnessing a surge in diabetes and obesity cases, creating a vast market opportunity for the U.S.-based pharmaceutical giant.
Mounjaro stands out in the pharmaceutical landscape due to its dual-action mechanism. It selectively binds to and activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors, playing a vital role in regulating blood sugar levels and appetite.
The drug is indicated for:
India is home to over 101 million people living with diabetes, with nearly half of them experiencing suboptimal glycemic control. Additionally, obesity, which is a chronic and relapsing disease, is a major risk factor for diabetes and has been linked to over 200 health complications, including:
According to Eli Lilly India President and General Manager Winselow Tucker, the “dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India.”
Mounjaro is already sold under the same brand name in the UK and Europe for both diabetes and weight management. In the U.S., it is marketed as Zepbound specifically for obesity.
Pharmaceutical analysts predict that the global obesity drug market will skyrocket to $150 billion annually by the early 2030s, making it one of the most lucrative segments in the healthcare industry.
ALSO READ: Drug For Weight Loss? Eli Lilly Launches Its Popular ‘Mounjaro’ In India
CIA Director John Ratcliffe said his communications within a messaging group were entirely lawful and…
Tamil actor Manoj Bharathiraja, son of director Bharathiraja, passed away at 48 due to cardiac…
Sunny Deol, at the Jaat trailer launch, praised South filmmakers, criticized Bollywood’s commercial approach, and…
In a phone conversation with NBC News, Trump said, "It was the only glitch in…
Bollywood superstar Salman Khan was also spotted at Lilavati Hospital, offering support to Jacqueline during…
We had to choose if we would stop there & let him go, or to…
